Acute Promyelocytic Leukemia News and Research

RSS
Acute promyelocytic leukemia (APL) is a subtype of acute myeloid leukemia (AML) and is characterized by a unique molecular abnormality. This type of leukemia has a high mortality rate and is associated with early hemorrhagic death.
Nexus announces availability of Arsenic Trioxide Injection in the US

Nexus announces availability of Arsenic Trioxide Injection in the US

Combination of arsenic and existing leukemia drug may combat cancer

Combination of arsenic and existing leukemia drug may combat cancer

Arsenic trioxide could be powerful therapy to extend lives of certain glioblastoma patients

Arsenic trioxide could be powerful therapy to extend lives of certain glioblastoma patients

Scientists identify new genetic variations contributing to onset of APL

Scientists identify new genetic variations contributing to onset of APL

Arsenic induces acute promyelocytic leukemia remission

Arsenic induces acute promyelocytic leukemia remission

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Sequencing the genomes of cancer patients help doctors decide the best course of treatment

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

Journal of Clinical Oncology publishes CytRx tamibarotene Phase 2b trial results in APL

Sequencing mouse cancer genome reveals mutations driving cancer in humans

Sequencing mouse cancer genome reveals mutations driving cancer in humans

Researchers use computers to capture chemical signal structure that triggers metastatic cancer

Researchers use computers to capture chemical signal structure that triggers metastatic cancer

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

BIDMC scientist wins 2011 Pezcoller Foundation-AACR International Award for cancer research

Research: Arsenic trioxide may benefit individuals with connective brain tumors

Research: Arsenic trioxide may benefit individuals with connective brain tumors

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

CytRx commences tamibarotene Phase 2b clinical trial in NSCLC

Study finds arsenic improves survival rate in APL patients

Study finds arsenic improves survival rate in APL patients

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

CytRx reports net income for second-quarter 2010 compared to net loss for previous year

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

Cytrx’s tamibarotene achieves molecular complete remission in advanced acute promyelocytic leukemia

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

SWCRF/Emerald Foundation Global Collaborative Grant to fund critical cancer research

CytRx plans five Phase 2 clinical trials with oncology drug candidates

CytRx plans five Phase 2 clinical trials with oncology drug candidates

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

Challenges in treating AML and recent updates to NCCN Guidelines presented at NCCN Annual Conference

CytRx announces its plans to advance multiple oncology development programs in 2010

CytRx announces its plans to advance multiple oncology development programs in 2010

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced

Results from CytRx's Phase 2 STAR-1 registration clinical trial for tamibarotene announced